News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:05 2024-04-23 pm EDT			After market 05:10:01 pm
149.5 ^USD	+0.28%		149.9	+0.23%

Apr. 22	J&J: EU green light for Carvykti in multiple myeloma	CF
Apr. 22	Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson to participate in the Bernstein's 40th Annual Strategic Decisions Conference	10:08am	AQ
Janssen - CARVYKTI is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	10:07am	AQ
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)	Apr. 22	BU
J&J: EU green light for Carvykti in multiple myeloma	Apr. 22	CF
Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	Apr. 22	PU
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
Contaminated cough syrup in Africa no longer available - WHO	Apr. 22	RE
WHO Likely to Issue Wider Warning About J&J Cough Syrup Contamination, Reuters Reports	Apr. 19	DJ
WHO says wider alert on contaminated J&J cough syrup 'likely'	Apr. 19	RE
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Medical device maker Intuitive beats estimates on strong demand for surgical robots	Apr. 18	RE
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
Johnson & Johnson : First Quarter 2024 2024 First-Quarter Earnings Transcript	Apr. 18	PU
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
Johnson & Johnson's Q1 Had 'Some Puts and Takes,' Morgan Stanley Says	Apr. 17	MT
Johnson & Johnson Reports Q1 2024 Results	Apr. 17	AQ
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase, Raises Quarterly Dividend by 4.2%	Apr. 17	AQ
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST